case_images: PMC10756667_01
case_images: Clinical and Diagnostic Progression in Patient with PPMS and SLE. (A) Computed Tomography (CT) image depicting extensive pleural effusion before treatment (indicated by red arrows) (2022-10-17). (B-C) Subsequent to the histopathological examination of the parietal pleura, the pathology report indicates the presence of lymphocytes, histiocytes, and normal mesothelial cells, with no discernible tumor cells identified. The red arrow signifies values exceeding the normal range. (D) Graph showing the progression of serum calcium concentration, with the left vertical axis indicating pleural effusion volume and the horizontal axis representing time. Ultrasonography assessed the pleural effusion volume, with the first week of patient admission as the starting point. (E) Subsequent CT image illustrating a significant reduction in pleural effusion post-treatment (2022-11-16). (F) Cytokine concentration in both serum and pleural effusion before the initiation of immunosuppressive therapy.
case_images: fimmu-14-1277683-g001.jpg
case_images: PMC10756667_01_fimmu-14-1277683-g001.jpg
case_images: f1
case_images: Approximately ten months before hospitalization, she developed recurring dry cough and pronounced knee pain, prompting a computed tomography (CT) scan that revealed bilateral pleural effusions ( Figure 1A ). To ascertain a diagnosis, a right-sided medical thoracoscopy was performed, revealing interstitial lung inflammation with lymphoid follicular hyperplasia and pleural fibrous thickening ( Figures 1B, C ). CA-125 consistently exceeding 1300 U/mL, peaking at 2767 U/mL ( Figure 1D ). Comprehensive evaluations excluded cardiac, thyroid-parathyroid, abdominal, and cranial abnormalities, while vaginal ultrasound indicated physiological findings. The assessment of pleural effusion volume revealed a significant reduction ( Figure 1E ).